Suppr超能文献

新冠病毒检测呈阳性患者的细菌合并感染及抗生素耐药性评估

Evaluation of Bacterial Co-Infections and Antibiotic Resistance in Positive COVID-19 Patients.

作者信息

Marua Alpesh M, Shethwala Nimisha D, Bhatt Parth, Shah Amar

机构信息

Department of Pathology, Dr. N. D. Desai Faculty of Medical Science and Research, Nadiad, India.

Department of Microbiology, GMERS Medical College, Himmatnagar, India.

出版信息

Maedica (Bucur). 2022 Jun;17(2):350-356. doi: 10.26574/maedica.2022.17.2.350.

Abstract

Due to the fact that patients with COVID--19 can have a bacterial co-infection, physicians should be careful when prescribing antibiotics, with rather considering the sensitivity and resistance of these drugs than various bacteria. Therefore, the main purpose of the present study was to evaluate bacterial coinfections and antibiotic resistance in positive COVID-19 patients. This descriptive cross-sectional study was performed on 450 hospitalized COVID-19 patients who were selected by simple random sampling. Blood culture (BC) and endotracheal aspirate (ETA) were performed for all COVID-19 patients participating in the study. Antibacterial susceptibility was assessed using the standard Kirby-Bauer disk diffusion method on Mueller Hinton agar for all isolated strains in accordance with the Institute of Clinical and Laboratory Standards guidelines. Finally, susceptibility of all identified bacteria to 10 types of antibiotics was assessed. Based on the results of endotracheal aspirate (ETA) culture, we found that 79 (17.5%) patients had COVID-19 and bacterial co-infection. Among COVID-19 patients with bacterial co-infection, Klebsiella species had the highest frequency (21.6%), followed by Methicillin-sensitive Staphylococcus aureus (MSSA) (19%), Escherichia coli (17.7%), Methicillin-resistant Staphylococcus aureus (MRSA) (15.2%), Enterobacter species (13.9%) and Pseudomonas aeruginosa (12.6%), respectively. Based on the results of the present study, it was found that the level of antibiotic resistance for different bacteria varied from 0-100%. The results of the present study indicate that patients with COVID-19 are susceptible to bacterial co-infection, which leads to the conclusion that excessive use of antibiotics is an important factor in the development of antimicrobial resistance. Therefore, caution is needed in prescribing different antibiotics to patients with COVID-19. In addition, considering the SARS-CoV-2 co-infection with other pathogens, it is necessary to use an optimal treatment method for this purpose.

摘要

由于新冠肺炎患者可能存在细菌合并感染,医生在开具抗生素处方时应谨慎,更应考虑这些药物的敏感性和耐药性,而非各种细菌。因此,本研究的主要目的是评估新冠肺炎阳性患者的细菌合并感染情况及抗生素耐药性。本描述性横断面研究对450例通过简单随机抽样选取的住院新冠肺炎患者进行。对所有参与研究的新冠肺炎患者进行血培养(BC)和气管内吸出物(ETA)检测。根据临床和实验室标准协会指南,使用标准的 Kirby-Bauer 纸片扩散法在 Mueller Hinton 琼脂上对所有分离菌株进行抗菌药敏试验。最后,评估所有鉴定出的细菌对10种抗生素的敏感性。根据气管内吸出物(ETA)培养结果,我们发现79例(17.5%)患者存在新冠肺炎合并细菌感染。在合并细菌感染的新冠肺炎患者中,克雷伯菌属的感染频率最高(21.6%),其次分别是甲氧西林敏感金黄色葡萄球菌(MSSA)(19%)、大肠杆菌(17.7%)、甲氧西林耐药金黄色葡萄球菌(MRSA)(15.2%)、肠杆菌属(13.9%)和铜绿假单胞菌(12.6%)。根据本研究结果,发现不同细菌的抗生素耐药水平在0%-100%之间。本研究结果表明,新冠肺炎患者易发生细菌合并感染,由此得出结论:过度使用抗生素是导致抗菌药物耐药性产生的重要因素。因此,在为新冠肺炎患者开具不同抗生素时需要谨慎。此外,考虑到SARS-CoV-2与其他病原体的合并感染,有必要为此采用最佳治疗方法。

相似文献

本文引用的文献

4
Co-infections: potentially lethal and unexplored in COVID-19.合并感染:在新冠病毒病中可能致命且未被探索。
Lancet Microbe. 2020 May;1(1):e11. doi: 10.1016/S2666-5247(20)30009-4. Epub 2020 Apr 24.
5
Tackling antimicrobial resistance in the COVID-19 pandemic.应对新冠疫情中的抗菌药物耐药性问题。
Bull World Health Organ. 2020 Jul 1;98(7):442-442A. doi: 10.2471/BLT.20.268573.
7
Pneumococcal coinfection in COVID-19 patients.新冠病毒感染患者中的肺炎球菌合并感染
J Med Virol. 2021 Jan;93(1):177-179. doi: 10.1002/jmv.26278. Epub 2020 Jul 17.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验